Prognostic value of pre-transplant PET/CT in patients with diffuse large B-cell lymphoma undergoing autologous stem cell transplantation. Issue 5 (4th May 2018)

• Record Type: Journal Article
• Authors: Winter, Allison; Rybicki, Lisa; Shah, Shetal N.; Jagadeesh, Deepa; Gerds, Aaron T.; Hamilton, Betty K.; Liu, Hien; Dean, Robert; Sobecks, Ronald; Pohlman, Brad; Smith, Mitchell; Kalaycio, Matt; Bolwell, Brian J.; Majhail, Navneet S.; Hill, Brian T.
• Is Part Of: Leukemia & lymphoma. Volume 59:Issue 5(2018)
• Page Start: 1195
• Page End: 1201
• Publication Date: 2018-05-04
• Subjects: Lymphoma and Hodgkin disease -- prognostication -- clinical results; Leukemia -- Periodicals; Lymphomas -- Periodicals; 616.99419
• DOI: 10.1080/10428194.2017.1369065
• Languages: English
• ISSNs: 1042-8194

Abstract

Abstract: Pre-transplant PET/CT may be prognostic in diffuse large B-cell lymphoma (DLBCL) patients undergoing autologous stem cell transplantation (ASCT). We reviewed relapsed and pre-transplant PET/CT scans of 32 patients with DLBCL treated with ASCT to determine the Deauville score and the maximum standardized uptake value (SUVmax ). Patients with a Deauville score of 4 had a significantly inferior prognosis. The 3-year progression-free survival (PFS) for patients with Deauville 1–3 score was 64%, compared to 0% for Deauville 4, while the 3-year overall survival (OS) was 84% and 25%, respectively ( p < .001, p = .002). The change in the SUVmax (>66 versus ≤66%) was not predictive of PFS or OS, but a high pre-transplant SUVmax (>6) demonstrated a trend towards an inferior PFS. Pre-transplant PET/CT is a tool for identifying DLBCL patients at high risk for treatment failure with ASCT and could be used to risk-stratify patients in prospective clinical trials of novel transplant strategies.